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Return on investment (ROI) is a ratio that has come into increasing
use over recent years. ROI indicates how much economic beneﬁt is de-
rived from a program in relation to its costs. This ratio, calculated to
demonstrate how relevant investments are, has the esthetic quality of
being remarkably synthetic. Both private sector and non-proﬁt ﬁrms
use it to stimulate co-investments. Foundations, for example, seek to at-
tract more funds for their activities by demonstrating to their funding
partners that money is wisely invested. In recent years, there has been
growing research interest in ROI use in the public health sector,(Baxter
et al., 2014; APHA, 2013; CPHA, 2013) mainly to demonstrate the eco-
nomic value of public health programs in a context of rationed public
spending. In this paper, we explore the beneﬁts and risks of using ROI
to defend public health programs. The issue is salient because ROI-
based public decisions will necessarily inﬂuence the public good and
people's well-being and may have an impact on resource allocation
and use. To orient our discussion, we present two recent examples of
ROI use in public health and explore the context within which its use
is expanding in public health economic evaluation. We then discuss
the beneﬁts and risks of using ROI to defend public health programs.
Lastly, we offer proposals for using ROI information while acknowledg-
ing the full range of impacts of programs.euil, Université de Sherbrooke,
rousselle).
. This is an open access article underROI in public health
Both the American Public Health Association (APHA) and the
Canadian Public Health Association (CPHA) recently launched videos
showing returns on investment for various programs, advocating that
“investing in public health is smart” (APHA, 2013; CPHA, 2013). In
these videos (see screenshots in Fig. 1), programs are compared in
terms of their different ROI ratios. Some of the key CPHAmessages are:
Every $1 spent on early childhood health and development saves up
to $9 in future spending on health, social and justice services. Return
on investment: 800%.
Every $1 invested in tobacco prevention programs saves up to $20 in
future health care costs. Return on investment: 1900%.
The CPHAvideo concludes by saying, “Public health is a return on in-
vestment…Make investing in public health a priority.” The APHA video
ends with the same message: “Public health is a return on investment:
prioritize public health funding.”
Clearly, using ROI in the public sector is a way to defend public
health programs in a context where funding is threatened, budgets are
controlled, and the relevance of public health interventions still needs
to be justiﬁed (Stine & Chokshi, 2012; Ifanti et al., 2013; Potvin, 2014).
While this particular trend is new, comparing costs to economics bene-
ﬁts has a long-standing history in theﬁeld of economic evaluation. Cost-
offset and ROI studies have been around for years (Kelly, 2005;
Neumann et al., 2008; Chattopadhyay & Carande-Kulis, 2004; Drum-
mond et al., 2008; Brent, 2003).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Screenshots from Public Health: A Return on Investment (left, CPHA) and Public Health is ROI (right, APHA).
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takings (Shiell et al., 2008). A signiﬁcant proportion of them target
effects produced over the long term whose impacts are diffuse and
may affect a variety of sectors (e.g. health, education, employment)
(Alayli-Goebbels et al., 2013). Their adverse effects, which do exist, are
also difﬁcult to document (Drummond et al., 2008; Goldsmith et al.,
2004; Brousselle & Lessard, 2011; Coast, 2004; Weatherly, 2007;
Killoran et al., 2009). Many of these interventions also have externali-
ties, in that they affect people not directly targeted by the intervention.
Finally, the nature of these interventionsmakes it difﬁcult to use exper-
imental designs, and, when measuring the effects, researchers must
contend with both contextual inﬂuences and those of concurrent inter-
ventions. These characteristics render causal relationships very com-
plex, such that it is not often easy to attribute observed effects to a
given intervention (Shiell et al., 2008). Identifying effects, measuring
them, and attributing value to them are challenges in themselves
(Alayli-Goebbels et al., 2013; Weatherly et al., 2009; Chalkidou et al.,
2008). All these characteristics may explain why economic evaluations
of public health programs and interventions have traditionally been
under-represented in published economic evaluations (Drummond
et al., 2008; Goldsmith et al., 2004; Weatherly, 2007; Killoran et al.,
2009). Most economic evaluation studies deal with new technologies
or drugs, while fewer than 10% address upstream interventions such
as public health interventions,(Rush et al., 2002) with the majority
(55%) of those targeting clinical prevention (Goldsmith et al., 2004).
In recent years, an emerging movement has provoked in-depth re-
ﬂection onwhat economic evaluation methods are best suited to public
health programs and interventions. The publication of the Wanless
report (Allin et al., 2005) and the creation of the NICE Centre for Public
Health Excellence in the United Kingdom have prompted considerable
questioning and redeployment of economic evaluation methods for
public health programs and interventions (Kelly, 2005). These reﬂec-
tions found concrete expression in the NICE report Supporting Invest-
ments in Public Health, published in 2011 (NICE, 2011). In Canada, a
similar reﬂection occurred, (PHAC, 2009) resulting in a report that pro-
posed a way to grasp the complexity of public health programs using
economic evaluation methods (Husereau et al., 2014). It is important
to note that all these published reports give new prominence to the
valuation of impacts. They explicitly suggest including complementary
information on ROIs (NICE, 2011) or “some estimate (or valuation) of
the monetary value of added improvement in health outcomes”
(Husereau et al., 2014). These publications are examples of the new
trend of using ROIs when conducting economic evaluations of public
health programs and interventions. They have also helped to institu-
tionalize this approach, with the consequence that ROIs are now being
used not only in advocacy efforts, but also, and more importantly, in
decision-making on resource allocation. This new prominence given toROI in public health raises the need for thoughtful reﬂection on the
beneﬁts and risks of this orientation.Beneﬁts and risks
Beneﬁts
In 2008, Neumann et al. observed that:
“The value of governmental public health systems may seem ob-
vious in light of progress in public health over the past century.
The reality of chronic underfunding of these systems suggests
that the general public is unaware of public health's value”
(p. 2173)(Neumann et al., 2008).
Funding for public health has always been difﬁcult to secure
(Freedman et al., 2013; CPHA, 2010; Robert Wood Johnson Foundation,
2013). Even though public health programs and interventionsmay lead
to important population health gains, in our society, medical care still
receives the larger portion of funding (Robert Wood Johnson
Foundation, 2013). In recent years, in Canada and in the United States,
public health expenditures represented 5.3% and 3% of total health
spending, respectively (CIHI, 2013; Harvard and Chan, 2012; Institute
of Medicine, 2012). In contexts where public expenditures are being re-
duced, there is a real risk that the proportion of resources devoted to
public health will shrink. Public health has historically contributed to
changing the epidemiological proﬁle of societies. Today's public health
challenges, which include chronic diseases, life course epidemiology,
and environmental health issues, call for multisectoral interventions.
ROI is a timely tool with which to advocate for public health inter-
ventions that have long term implications and require substantial
investments. Assessing the economic value of public health programs
and interventions using ROIs, cost-offsets, and proﬁtability threshold
analysis could provide robust arguments in their defense. First, it
would turn the discourse around, such that the public health budget
would no longer be seen as an expense, but rather as an investment
that is often proﬁtable over the short, medium, or long terms. Second,
in a context of controlling public expenditures, such arguments might
inﬂuence public opinion and ultimately help safeguard funding for pub-
lic health programs and interventions. Third, for public health interven-
tions with demonstrated savings, the issue would no longer be their
worthiness as ﬁnancial investments, but rather their affordability, as
the question then becomes: even if we know the beneﬁts outweigh
the costs, can we afford to invest today in a public health intervention
whose effects will only manifest over the longer term? Affordability
might present the next serious obstacle to funding, and budget impact
analysis may be necessary as complementary decisional information.
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Even if there are known beneﬁts to using ROIs in relation to public
health interventions, there are also several risks. First, using ROIs inevi-
tably engenders comparisons. For instance, using the two previously
mentioned videos, we ranked the ROIs for various public health pro-
grams (Table 1). A cursory look at the results prompts questions such
as this one: given that the ROI of water ﬂuoridation is twice that of
early education programs, should water ﬂuoridation have priority
over early education? If allocation decisions were based only on ROI,
would it mean interventions with the lowest ROIs should not be
funded?
Taking ROIs into account in allocation decisions may considerably
change which interventions are funded and which are not. Decision-
makers may wish to stop funding interventions that do not show a
positive ROI. What would these interventions be? Who would be the
losers? Andwhat would the social impacts be of reallocation decisions?
Finally, howwould innovation and experimentation be funded if show-
ing a positive ROI became a condition of funding?
Second, there are important concerns related to the way ROIs are cal-
culated. As discussed earlier, public health interventions are complex,
with effects that are sometimes scattered and intangible and with exter-
nalities that are neither easily quantiﬁable nor easily convertible into dol-
lars (Shiell et al., 2008; Goldsmith et al., 2004; Payne et al., 2013). ROI
calculation readily accommodates medical costs averted with improved
health (e.g. reduced hospitalizations related to asthma, shortness of
breath, lung cancer treatment), but assigning dollar values to life-years
saved, to intangible effects such as increased well-being or empower-
ment, and to externalities is not so easy. While some evaluators do not
hesitate to attribute an economic value to life-years saved, this is still
very much subject to ethical debate (Drummond et al., 2005; Pinkerton
et al., 2002; Robinson, 1993; Kelman, 1981; Mooney, 1980; Weinstein &
Fineberg, 1980;Mishan, 1971). On the other hand, not including these ef-
fects because of a conviction, on principle, that they should not be con-
verted into dollars will inevitably favor interventions with more acute
and easily measurable impacts. Finally, whereas public policies and orga-
nizations advocate for the importance of integrating equity consider-
ations into public health evaluations (World Health Organization, 1986).
ROI methodology has no way of taking into account equity beneﬁts,
such that these consequences do not ﬁgure in the calculation.Discussion
The mission of public health is to prevent diseases and traumas and
to protect andpromote health (WorldHealthOrganization). In austerity
contexts, ROIs can offer reassurance on the economic value of public in-
vestments in this sector (Stuckler & Basu, 2014). However, quantifying
the economic beneﬁts of public health programs can also lead to people
being seen as inputs into the overall economic system, with no intrinsicTable 1
Examples of public health intervention ROIs, ranked highest to lowest.
Intervention ROI Source
Child safety seat 3900% CPHA and APHA
Water ﬂuoridation 3700% CPHA and APHA
Mental health and addiction 3600% CPHA
Tobacco prevention 1900% CPHA
Vaccination 1500% CPHA
Early education 1300% APHA
Biking and walking opportunities 1200% APHA
Food and nutrition 1000% APHA
Childhood health and development 800% CPHA
Workplace safety 500% CPHA and APHA
Cleaner vehicles 300% CPHA
Tobacco cessation 125% APHA
Sources: APHA, CPHA.value other than the economic advantages their health and activities
can provide.
Public health has a value in itself, as it has the potential to positively
impact the health of humans. Nevertheless, every public investment has
an opportunity cost: when we decide to invest in one program, our
capacity to invest in another is reduced. There is no reason why public
health should be exempt from this predicament. How, then, are we to
be guided in these considerations? Based on the above discussion, we
propose the following guidelines to minimize risks associated with
using ROIs to defend public health interventions:
(1) Defend public health programs for what they do. ROIs should not
be central to the discussion, but rather should be seen as comple-
mentary information to be considered after effectiveness indica-
tors. Furthermore, we must always keep in mind that cost and
beneﬁt data are eminently contextual and that, as such, ROIs can-
not be exported to other contexts than those used for the study.
(2) ROIs should only be used for equivalent alternatives and not to
compare interventions that are different in their objectives.
(3) To avoid ethical questions, it would be judicious and sufﬁcient
simply to assess whether beneﬁts outweigh costs, without
attempting to identify, calculate and translate into dollars all
the effects of public health interventions and programs
(Tchouaket et al., 2013).
(4) For programs thatmay be threatened by ROI comparison, it could
be useful to anticipatewhat the impacts of stopping their funding
would be.
(5) The effectiveness of public health programs should be systemat-
ically documented. There is a dearth of reliable data on public
health programs; evaluative efforts should be intensiﬁed to
adapt methodological approaches and compile more evidence.
(6) Finally, greater use should be made of logic models. Based on
evaluation methodologies, the logic model shows the resources
invested in an intervention, as well as the activities and the
chain of effects, including direct effects (e.g. morbidity, mortali-
ty), indirect effects (e.g. reduced utilization of health care and
of professional resources in schools, fewer work days lost) and
externalities (protection of other individuals) (Funnell &
Rogers, 2011). Logic models are a powerful tool to represent all
the effects, both those included in ROI calculations and those
that are not.
Conclusion
ROIs are increasingly being calculated to demonstrate the value of
investments and ultimately to reinforce funding (Gargani, 2014; King,
2014). Consequently, careful reﬂection is needed onhow their use inﬂu-
ences allocation decisions. ROIs of public health interventions are help-
ful to introduce economic information into the political debate and are
used mainly as an advocacy tool in the political arena. It is therefore
crucial to understand the basics of how ROIs are calculated and to
know their limitations and risks, rather than blindly accepting black-
box numbers.
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